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Abstract
Background: The present study validates a symphysis-fundal height chart (SFH-chart) for pregnant women with
type 2 diabetes mellitus (DM2), gestational diabetes mellitus (GDM) and mild gestational hyperglycemia (MGH)
attending at the Diabetes and Pregnancy Reference Service of the Botucatu Medical School, UNESP, Brazil.
Methods: A cross-sectional study was carried out to evaluate the performance of the specific FHC in predicting
small (SGA) and large (LGA) for gestational age newborns (NB). We evaluated 206 pregnant women with DM2,
GDM or MGH and their NB. The last symphysis-fundal height measure, taken at birth, was used to determine the
sensitivity index (Sens), specificity index (Spe), positive prediction value (PPV), negative prediction value (NPV) and
accuracy in predicting SGA and LGA. The gold standard was the Lubchenco birth weight/gestational age ratio
evaluated at birth.
Results: The mothers showed adequate glycemic control; 91.3 % of all pregnant women achieved HbA1c < 6,5 %
in the third trimester. The SFH-chart tested achieved 100 % of Sens and NPV in predicting both SGA and LGA, with
accuracy of 90.3 % (85.5; 93.6) and 91.8 % (87.2; 94.8), respectively, for predicting SGA and LGA newborns.
Conclusions: The Basso SFH-chart showed high performance in predicting both SGA and LGA newborns of DM-2,
GDM and MGH mothers, with better performance than the national reference SFH-chart. These findings support the
internal validation of the Basso SFH-chart, which may be implemented in the prenatal care of the Diabetes and
Pregnancy Reference Service-Botucatu Medical School/UNESP.
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Background
The reference symphysis-fundal height chart (SFH-chart)
recommended by the Brazilian Health Ministry [1] was
developed by the Latin American Center of Perinatology
and Human Development (CLAP) and published in 1984
[2]. In developing countries, it is the primary if not the only
tool for measuring fetal growth [3]. Other studies suggest
the development of specific SFH-charts for each country,
that is, based on the main population features [4–6]. As
such, Brazilian studies have created new SFH-charts that
are more suitable for their population [3, 7–15]. The most
recent SFH-charts show significant contrasts in relation to
the reference national SFH-chart [1, 2], which is more sen-
sitive in identifying newborns that are small for gestational
age (SGA-NB) [3, 13, 15].
Given the unsuitability of the national reference SFH-
chart [1, 2] and the lack of specific SFH-charts for risk
pregnancy, Basso [16] developed an SFH-chart for preg-
nancies complicated by diabetes and hyperglycemia. The
Basso SFH-chart was based on 2470 symphysis-fundal
height measures taken between 13 and 41 weeks of
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gestation, in 422 pregnant women with type 2 diabetes
mellitus (DM2), gestational diabetes mellitus (GDM)
[17] and mild gestational hyperglycemia (MGH) [18]
under adequate glycemic control, with maternal gly-
cemic mean < 120 mg/dL and/or HbA1c < 6,5 % [17, 18].
The Basso SFH-chart [16] differs significantly from
the national reference SFH-chart [1, 2] and those
developed by Oppermannn et al. [3] and Freire et al.
[15] for Brazilians with low risk pregnancy. It was
shown to be more appropriate than the others in pre-
dicting large for gestational age newborns (LGA-NB)
because its percentiles exhibit higher values for most
pregnancy weeks (P10 to P90). It is therefore more
suitable for accompanying pregnancies complicated by
DM2, GDM and MGH, which commonly result in
larger babies. However, the diagnostic performance of
the SFH-chart has yet to be tested on pregnant
women with the aforementioned disorders [16]. In
this sense, the present study aimed at validating the
Basso SFH-chart [16] developed for pregnant women
with DM2, GDM and MGH. To that end, the Basso




This observational study was carried out to validate the
diagnostic performance of Basso SFH-chart [16] specific
for pregnant women with DM2, GDM and MGH
(Table 1 and Fig. 1). It was performed at the Diabetes
and Pregnancy Reference Service of the Botucatu
Medical School, UNESP, Sao Paulo, Brazil (SEDG-FMB/
UNESP). The Human Research Ethics Committee of the
Botucatu Medical School/UNESP approved the research
project under protocol # 255/08.
All pregnant women attending at SEDG-FMB/UNESP
in the period, and that met the inclusion criteria, were
included in this study. As described in Basso study [16],
the following inclusion criteria were adopted: (i) preg-
nant women with DM2, GDM or MGH; (ii) treated at
SEDG-FMB/UNESP during the prenatal period (which
involves at least five prenatal visit) and at birth; (iii)
gestational age confirmed by early ultrasound (until 20
weeks); (iv) having a singleton pregnancy with live fetus;
and (v) signing an informed consent form. A total of 206
pregnant women and their newborns were included in
the study.
Data collection
Data were obtained from the SEDG-FMB/UNESP data-
base, which was updated daily with information acquired
from every prenatal visit and hospitalization period,
including the time of birth. Data were analyzed in
Microsoft Excel 2003® spreadsheets.
Subjects were characterized according to maternal age
(years), pre pregnancy body mass index (BMI) [19],
number of gestations and gestational age at birth. The
type of hyperglycemia condition was categorized accord-
ing to Priscila White’s prognostic classification [20] and
Rudge’s diagnostic criteria [18]. Glycated haemoglobin
(HbA1c) was determined at late pregnancy to identify
the quality of glucose control in the third trimester, con-
sidering levels < 6.5 % as adequate [17].
Table 1 Expected value, lower and upper bounds of a 95 %
confidence interval on Basso SFH-chart [16]* between 13
and 42 weeks of pregnancy complicated by diabetes and
hyperglycemia
FH = 1.082 + 0.966*week
FH (lower bound) = 0.629 + 0.95*week
FH (upper bound) = 1.535 + 0.981*week
Confidence interval 95 %
Week Expected FH Lower bound Upper bound
13 13.64 12.98 14.29
14 14.61 13.93 15.27
15 15.57 14.88 16.25
16 16.54 15.83 17.23
17 17.50 16.78 18.21
18 18.47 17.73 19.19
19 19.44 18.68 20.17
20 20.40 19.63 21.16
21 21.37 20.58 22.14
22 22.33 21.53 23.12
23 23.30 22.48 24.10
24 24.27 23.43 25.08
25 25.23 24.38 26.06
26 26.20 25.33 27.04
27 27.16 26.28 28.02
28 28.13 27.23 29.00
29 29.10 28.18 29.98
30 30.06 29.13 30.97
31 31.03 30.08 31.95
32 31.99 31.03 32.93
33 32.96 31.98 33.91
34 33.93 32.93 34.89
35 34.89 33.88 35.87
36 35.86 34.83 36.85
37 36.82 35.78 37.83
38 37.79 36.73 38.81
39 38.76 37.68 39.79
40 39.72 38.63 40.78
41 40.69 39.58 41.76
42 41.65 40.53 42.74
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The SFH measures throughout pregnancy (13 to 41
weeks) were plotted on Basso SFH-chart [16]. The last
measure, taken at birth, was used to calculate the values
and confidence intervals (at 95 %) of the sensitivity index
(Sens), specificity index (Spec), positive predictive value
(PPV) and negative predictive value (NPV), and determine
its accuracy in predicting small and large for gestational
age newborns (SGA-NB and LGA-NB, respectively). The
newborns were classified according to Lubchenco birth
weight/gestational age ratio [21], which was used as gold
standard to evaluate the Basso SFH-chart performance to
predict SGA and LGA newborns.
Subjects follow-up
According to SEDG-FMB/UNESP protocol [18], the
diabetic pregnant women (type 2-DM) were immediately
submitted to the glycemic control, with individual
nutritional prescription and light to moderate-intensity
exercises (walking 30 min five times a week), and
received insulin from the first evaluation.
To diagnostic of GDM or MGH, were used the oral
glucose tolerance test (75g-OGTT) and glycemic profile
(GP), independently performed between 24 and 28 ges-
tational weeks. The pregnant women with confirmed
GDM or MGH were introduced to the same nutrition
and exercise treatment protocol to achieve the glycemic
control, and insulin was introduced when necessary [18].
The maternal glycemic control was evaluated by GP
with fasting, pre- and post- prandial glycemic levels for
24 h in 2-week intervals until 32nd week, and weekly
until delivery. A good glycemic control was achieved by
glycemic mean < 120 mg/dL and/or HbA1c < 6.5 %.
GDM or MGH pregnant women with adequate glycemic
control and fetal growth waited for spontaneous labor
until 39–40 weeks; those with no adequate glycemic
control and/or fetal growth, and all type 2-DM have
their delivery programmed about 37 weeks [18].
Statistical analysis
The distribution of symphysis-fundal height measures
on the Basso SFH-chart was performed using IBM SPSS
Statistics 20.0 software. McNemar’s test evaluated the
performance of Basso SFH-chart [16] and of the national
reference SFH-chart [1, 2] in predicting SGA- and LGA-
newborns.
Results
The subjects profile (Table 2) shows that most were aged
25 years or older, with BMI corresponding to overweight
and obesity, and at least one previous pregnancy. Of the
206 women analyzed, 104 (50.5 %) exhibited GDM and
29 (14.1 %) DM2, and according to Rudge diagnostic cri-
teria [18], 73 (35.4 %) suffered from MGH. Mean mater-
nal HbA1c level in the third trimester was 6.0 ± 1.06 %;
188 (91.3 %) pregnant women had adequate glycemic
control, with HbA1c levels ≤ 6.5 %.
The women provided 980 symphysis-fundal height
measures (mean = 4.76 measures each) between 24 and
38 weeks of pregnancy. The maximum number of mea-
sures per gestational age was 93 (for 34 weeks) and 104
(for 37 weeks). The measures were plotted on Basso
SFH-chart [16] (Fig. 2).
Table 3 shows the distribution of the newborns ac-
cording to Lubchenco birth weight/gestational age ratio
[21]. The performance of Basso SFH-chart to predict
SGA- and LGA-newborns showed 100 % of Sens and
VPN for both SGA and LGA newborns. The accuracy
of the Basso SFH-chart was 90.3 % (85.5; 93.6) for
Fig. 1 Basso SFH-chart [16] developed for pregnant women with type 2-DM, GDM or mild gestational hyperglycemia (MGH)
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detecting SGA, and 91.8 % (87.2; 94.8) for identifying
LGA. The Sens and NPV values on Basso SFH-chart
[16] for predicting both SGA and LGA were higher
than those on the national reference SFH-chart [1, 2]
(Table 4).
Discussion
Our findings validate Basso SFH-chart [16], developed
for DM2, GDM and MGH pregnant women with
adequate glycemic control. The Basso SFH-chart [16]
identified all the cases of intrauterine growth devi-
ation, with respect to both growth restriction and
excessive growth. The national reference SFH-chart
[1, 2] showed a lower sensitivity index for predicting
LGA-NB (66.7 %) and identified less than 40 % of
SGA-NB (sensitivity = 38.9 %).
Compared to the results obtained with the national
reference SFH-chart [1, 2], the most recent SFH-charts cre-
ated for low-risk Brazilian pregnant women showed higher
sensitivity in detecting SGA-NB [3, 13–15, 22]. The pio-
neering results of Belizan et al. [23] exhibited 86 %
sensitivity, 90 % specificity and 10% false positive
results in identifying growth-restricted fetuses, validat-
ing symphysis-fundal height measurements in the
routine prenatal care. Thus, the findings of our study,
with 100 % sensitivity, 89.6 % specificity, and no false
positives in detecting SGA-NB, indicate the suitability
of the Basso SFH-chart [16] for assessing growth
Table 2 Characterization of the pregnant women studied
N Frequency (%)
≥25 years of age 180 87.4
BMI≥ 25 Kg/m2 152 73.8
≥1 previous delivery 146 70.9
Birth≥ 37 weeks 189 91.7
P White classificationa [n = 133]
A [diet controlled GDM] 83 62.4
A/B [diet + insulin controlled GDM] 21 15.8
B to C [DM2, no vascular diseases] 25 18.8
D to FRH [DM2, with vascular diseases] 4 3.0
Rudge groupsb [n = 206]
IIA [abnormal GTT, normal GP] 15 7.3
IIB [abnormal GTT, abnormal GP] 118 57.3
IB [normal GTT, abnormal GP] 73 35.4
HbA1c < 6,5 % [3rd trimester] 188 91.3
aPriscilla White’s prognostic classes [20] for diabetes in pregnancy: GDM
(gestational diabetes) and DM2 (type 2 diabetes)
bRudge’s diagnostic criteria for hyperglycemia in pregnancy [18] with
the association glucose tolerance test (GTT) + glucose profile (GP)
IIA: GDM, with abnormal gestational GTT and normal gestational GP
IIB: GDM, with abnormal gestational TTG and GP; or DM2, with abnormal
pre-pregnancy GTT
IB: mild gestational hyperglycemia (MGH), with normal gestational GTT
and abnormal gestational GP
Fig. 2 Distribution of 960 symphysis-fundal height measurements in this study plotted in Basso SFH-chart [16]
Table 3 Newborn distribution into birth weight classes
according Basso SFH-chart [16] and Lubchenco et al. [21]
Lubchenco et al. [21]
Basso SFH-chart [16] SGA N-SGA Total
SGAa 13 20 33
Not SGA 0 173 173
Total 13 (6.3 %) 193 (93.7 %) 206
Lubchenco et al. [21]
Basso SFH-chart [16] LGA N-LGA Total
LGAb 28 17 45
No LGA 0 161 161
Total 28 (13.6 %) 178 (86.4 %) 206
aSGA: small for gestational age newborn
bLGA: large for gestational age newborn
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restriction in pregnancies complicated with diabetes
or hyperglycemia.
Regarding LGA-newborns, the Basso SFH-chart [16]
identified all newborns with this condition, achieving
100 % of sensitivity; the sensitivity of the national refer-
ence SFH-chart [1, 2] was 66.7 %. In the Brazilian Study
of Gestational Diabetes (EBDG), the distribution of
symphysis-fundal height in the percentile 90 showed low
sensitivity (0.8 a 6.0 %) to identify LGA-newborns [3].
The SFH-chart developed by Freire et al. [15] in
Brazilian health pregnant women achieved sensitivity of
44.4 % and NPV of 89.4 % to predict LGA-newborns.
Based on these national references, the indexes of 100 %
sensitivity, 100 % NPV, 17 false positives (out of 178
cases), and no false negatives (28 cases) observed in our
study, reinforce the good performance of Basso SFH-
chart in identifying LGA-NB in pregnancies complicated
with hyperglycemia.
All the best of our knowledge, SFH-chart specific
for pregnancies complicated by diabetes or hypergly-
cemia had not yet been developed until Basso study
[16]. This highlight the originality of our investiga-
tion, but difficult the data analysis. Basso SFH-chart
[16] performed best in identifying both fetal growth
restriction and excessive fetal growth in pregnancies
complicated by diabetes and hyperglycemia. On the
other hand, the most recent SFH-charts developed for
the Brazilian population [3, 15] and the national
reference SFH-chart [1, 2] did not exhibit adequate
sensitivity indexes or NPV for this population.
Considering that Sensitivity and PPV are indicators
for a good diagnostic test [22], our results justify the
use of Basso SFH-chart in the prenatal care at SEDG-
FMB/UNESP.
However, some points must be reinforced. Similar to
Freire et al. [15], the Basso SFH-chart [16] was based on
data collected by a single observer, under controlled meth-
odological procedures. These methodological features
prevent the inter-observers bias. In the present study, al-
though the same technical protocol, different professionals
performed the symphysis-fundal height evaluation. Ac-
cording Oppermann et al. [3], this is a positive point to
improve the efficiency and reproducibility of the Basso
SFH-chart [16], and will likely contribute to its external
validation.
Other point is that the subjects of Basso SFH-chart
[16] have adequate glycemic control, and this character-
istic was not a criteria inclusion in our study. However,
our subjects and the population in the Basso study [16]
was from a same health service, subjected to similar
protocols for glycemic control, in general, resulting in
adequate glycemic control. In our study, the HbA1c
levels < 6.5 % in the end of gestation was achieved by
91.3 % (188/206) of all pregnant women. Besides, the
statistic power calculation, considering glycemic control
and gestational weeks, achieved 99.5 %. This findings
support the internal validation of the Basso SFH-chart in
our service.
Another question would be about the potential bias of
pre- or pregnancy-BMI, and the necessity of an adjusting
analysis by these variables. However, maternal BMI not
seem to have been decisive in the original study [16]; the
linear regression equation to predict SFH [SFH = 1.082
+ 0.966*gestational week] showed that SFH varied only
as a function of gestational age. Overweight or obesity is
a common characteristic in diabetic pregnant women,
constituting the physiopathologic base to insulin resist-
ance, and this is a reality in our service. BMI ≥ 25 Kg/m2
was present in 73.8 % and 62,3 %, respectively, here and
in Basso SFH-chart study [16]. BMI should be appreci-
ated in external validation of the Basso SFH-chart in
others services and subjects with different characteristics
of BMI.
The Basso SFH-chart performance to predict LGA-
and SGA-newborns was relative to late measures at
birth, that is, at least 37 weeks in 91.7 % (189/206) of all
Table 4 Performance diagnostic to SGA- and LGA-newborns according to the Basso SFH-chart [16] and the national reference
SFH-chart [1, 2]
SFH-chart [16] National reference SFH-chart [1, 2]
SGAa LGAb SGA LGA
Sens 100,0 (77,2; 100,0) 100,0 (87,9; 100,0) 38.9 (20,3; 61,4) 66.7 (47,8; 81,4)
Espec 89,6 (84,5; 95,2) 90,4 (85,2; 93,9) 100,0 (96,3; 100,0) 100,0 (95,9; 100,0)
PPV 39,4 (24,7; 56,3) 62,2 (47,6; 74,9) 100 (64,6; 100,0) 100,0 (82,4; 100,0)
NPV 100,0 (97,8; 100,0) 100,0 (97,7; 100,0) 90,1 (83,1; 94,4) 91,0 (83,8; 95,2)
Accuracy 90,3 (85,5; 93,6) 91,8 (87,2; 94,8) 90,7 (84,1; 94,7) 92,4 (86,1; 95,9)
SGA newborn [X2 = 18.05 (p < 0,001)c]
LGA newborn [X2 = 15.06 (p < 0,001)c]
aSGA: small for gestational age newborn
bLGA: large for gestational age newborn
cMcNemar’s Test
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cases. Our option was use the best (and real) gold stand-
ard, that is, the birth weight. Although not being the
best gold standard for fetal growth [24], the measure of
ultrasound abdominal circumference for each gestational
week would be another option, but this cannot be in-
cluded in our study. Either way, the distribution of our
SFH measures, just superimposed on the Basso SFH-
chart (Fig. 2), reinforces its validation.
Finally, the results of our study showed the high
performance to predict the birth weight deviations of
unique SFH-charts in pregnancies complicated by DM-
2, GDM, and MGH. To clinical practice, the Basso
SFH-chart [16] may be employed as a useful tool to C-
section indications for macrosomia at the SEDG-FMB/
Unesp. Another study using fetal ultrasound abdominal
circumference as the gold standard should validate its
use also to decisions on the maternal glycemic control
during pregnancy. Likewise, other studies are needed to
assess the reproducibility and external validation of
Basso SFH-chart [16] for use in different diabetic preg-
nancy reference centers.
Conclusion
The Basso SFH-chart [16] showed high performance in
predicting both SGA and LGA newborns of DM-2,
GDM and MGH mothers, with better performance than
the national reference SFH-chart [1, 2]. These findings
support the internal validation of the Basso SFH-chart
[16], which may be implemented in the prenatal care of
the Diabetes and Pregnancy Reference Service-Botucatu
Medical School/UNESP.
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